Clinical Trials Browser

Carcinoma, Small Cell

NCT01892527 2022-09-09

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Phase 2 Completed

43 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT01055067 2021-04-06

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Phase 2 Terminated

27 enrolled 6 charts

Seminoma

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

16 enrolled 11 charts

Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT01688973 2019-01-03

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

55 enrolled 16 charts

Genitourinary

Carcinoma, Renal Cell

NCT01696955 2018-12-19

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Phase 2 Completed

81 enrolled 14 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01519414 2018-09-12

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

78 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT01395758 2018-04-03

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

96 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01152645 2017-03-15

ARQ 197-004

Phase 2 Completed

31 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01861301 2016-10-24

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 7 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01575522 2016-03-21

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Completed

22 enrolled 10 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01580735 2015-08-18

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Phase 2 Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01070290 2014-01-07

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT00777309 2013-02-28

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

167 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00988741 2013-02-28

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Phase 2 Completed

107 enrolled

Tumor-Agnostic

Carcinoma

NCT00558207 2013-02-25

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Phase 2 Completed

43 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

Phase 2 Completed

47 enrolled

GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Clinical Trials

TIMES

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ARQ 197-004

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Phase 2 Study in Patients With MiT Tumors